Portfolio
Elegen
“A decade ago, fast and scalable DNA sequencing (reading) disrupted the life sciences, enabling a wave of new discoveries and high impact diagnostics and therapeutics. At Elegen, we believe the next frontier in the life sciences will be catalyzed by rapid, scalable DNA synthesis (writing). For decades, synthetic DNA has been an essential input into biomedical and biology research; high throughput sequencing and technologies such as CRISPR have further fueled demand for synthetic DNA. However, the technologies for synthesizing DNA have evolved only incrementally. The ability to generate an essentially unlimited variety of DNA quickly and cheaply will usher in a new era in the life and biomedical sciences. Elegen is developing a suite of ground-breaking technologies, with the promise to synthesize thousands of custom DNA sequences, inexpensively and on demand, in days instead of weeks.”
Founder: Matt Hill
Location: San Francisco, California
Category: Life Sciences / Services / Bio-Manufacturing
Company Stage: Series A
Co-Investors: a16z, 8VC, KdT Ventures, Digitalis, amongst others
